Holen Sie sich die Stockscreener-App
22.56
0.97%
-0.22
Handel nachbörslich:
23.00
0.44
+1.95%
Schlusskurs vom Vortag:
$22.78
Offen:
$23.36
24-Stunden-Volumen:
1.10M
Relative Volume:
0.97
Marktkapitalisierung:
$1.91B
Einnahmen:
$42.95M
Nettoeinkommen (Verlust:
$-130.01M
KGV:
-13.86
EPS:
-1.6278
Netto-Cashflow:
$-19.66M
1W Leistung:
-3.92%
1M Leistung:
+1.21%
6M Leistung:
-2.34%
1J Leistung:
+297.88%
1-Tages-Spanne:
$22.54
$23.65
1-Wochen-Bereich:
$22.37
$24.23
52-Wochen-Spanne:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
22.56 | 1.92B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics Inc (GLUE) Cash Flow - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Income Statement - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.780|Chg%:-0.250 - TradingKey
Price to sales forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics Market Sentiment - Benzinga España
Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE - TradingView
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - The Manila Times
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st
Enterprise value to revenue forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Nearly 9,500 Shares at $23.18 Average Price - Kalkine Media
Monte Rosa Therapeutics (GLUE) CEO sells 9,500 shares at about $23 each - Stock Titan
Form 144 MONTE ROSA THERAPEUTICS For: 16 July By Investing.com - Investing.com Nigeria
Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock - Investing.com UK
Price to book forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock By Investing.com - Investing.com Nigeria
Form 4 Monte Rosa Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics COO Jennifer Champoux Completes Stock Sales, Option Exercise, and New Grant Under Pre-Arranged Rule 10b5-1 Plan - Kalkine Media
Monte Rosa Therapeutics (GLUE) COO trades 4,351 shares via option exercise - Stock Titan
GLUE (NASDAQ: GLUE) holder to sell 9,500 shares under Rule 144 - Stock Titan
Enterprise value to EBIT forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position - MarketBeat
Monte Rosa COO Jennifer Champoux disposes of 4,351 common shares worth $101,707.28 - Bitget
GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise - Stock Titan
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build - simplywall.st
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE) - Stock Titan
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 - Investing.com
Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com - Investing.com India
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com - Investing.com Canada
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9%Should You Buy? - MarketBeat
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 13D/A Monte Rosa Therapeutics For: 6 July By Investing.com - Investing.com South Africa
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE) - Stock Titan
NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales - Stock Titan
GLUEMonte Rosa Therapeutics Inc Volatility & Greeks - Finviz
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):